Nippon Shinyaku FY26H1 Profit Down 12.3% to ¥3.8B, Revenues Up 7.4% Amid Output Constraints

Nippon Shinyaku (9988.T) reported for the first nine months of fiscal 2026 that net profit fell 12.3% year-over-year to ¥3.8 billion, while revenue rose 7.4% to ¥158.7 billion, according to the pharmaceutical company's results on February 9, 2026. The weakness in profit reflects continued output constraints and higher R&D and SG&A expenses, partially offset by strong sales growth in its core generics and vaccines segments. The company maintains a cautious outlook, citing soft demand in Japan and broader Asia-Pacific markets, and expects FY26 profit to remain volatile amid macroeconomic headwinds.